In this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed: 

1. ASC4FIRST RCT: Asciminib in newly diagnosed CML. 

https://pubmed.ncbi.nlm.nih.gov/38820078/

2. 5-year follow-up of ENESTnd RCT (nilotinib): 

https://pubmed.ncbi.nlm.nih.gov/26837842/

3. 10-year follow-up of ENESTnd RCT (nilotinib): 

https://pubmed.ncbi.nlm.nih.gov/33414482/

4. 10-year follow-up of CML-IV RCT (imatinib): 

https://pubmed.ncbi.nlm.nih.gov/25676422/

5. MD Anderson data on low-dose dasatinib (50 mg): 

https://pubmed.ncbi.nlm.nih.gov/36054032/

https://pubmed.ncbi.nlm.nih.gov/31553487/

6. CML: 2025 update on diagnosis, therapy, and monitoring: 

https://pubmed.ncbi.nlm.nih.gov/39093014/